VEGFR3 Antibody (YA4861)

Cat. No.: HY-P85169: Data Sheet User Guide for Antibodies
FAQs
Technical Support

VEGFR3 Antibody (YA4861) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to VEGFR3.

For research use only. We do not sell to patients.

Size		Stock
50 μL		Get quote
100 μL		Get quote

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

VEGFR3 Antibody (YA4861) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to VEGFR3.

Host

Mouse

Clonality

Monoclonal

Molecular Weight

Predicted band size: 153 kDa;

Species Reactivity

Human

SwissProt ID

P35916

Gene ID

2324 [NCBI]

Immunogen

Recombinant Human VEGFR3 protein

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:500-1:2000

Purity	affinity purified.	Conjugation	Non-conjugated
Modification	Unmodified

Appearance

Liquid

Formulation

Supplied in 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in human lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr-185', and of AKT1 at 'Ser-473'

Subcellular Localization：Cell membrane; Single-pass type I membrane protein; Cytoplasm; Nucleus; Cell membrane; Single-pass type I membrane protein; Cell membrane; Single-pass type I membrane protein; Secreted; Cytoplasm

Expression：
Tissue_specificity:Detected in endothelial cells (at protein level) . Widely expressed. Detected in fetal spleen, lung and brain. Detected in human liver, muscle, thymus, placenta, lung, testis, ovary, prostate, heart, and kidney

Isoforms & Post-Translational Modification：P35916 has 3 isomers: P35916-2: 152757 Da (predicted); P35916-1: 145599 Da (predicted); P35916-3: 93174 Da (predicted).
Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation in response to H(2)O(2) is mediated by a process that requires SRC and PRKCD activity. Phosphorylation at Tyr-1068 is required for autophosphorylation at additional tyrosine residues. Phosphorylation at Tyr-1063 and Tyr-1337 is important for interaction with CRK and subsequent activation of MAPK8. Phosphorylation at Tyr-1230, Tyr-1231 and Tyr-1337 is important for interaction with GRB2 and subsequent activation of the AKT1 and MAPK1/ERK2 and/or MAPK3/ERK1 signaling pathways. In response to endothelial cell adhesion onto collagen, can also be phosphorylated in the absence of FLT4 kinase activity by SRC at Tyr-830, Tyr-833, Tyr-853, Tyr-1063, Tyr-1333, and Tyr-1337

Subunit：Interacts with VEGFC and VEGFD. Monomer in the absence of bound VEGFC or VEGFD. Homodimer in the presence of bound VEGFC or VEGFD. Can also form a heterodimer with KDR.

Synonyms

FLT4; VEGFR3; Vascular endothelial growth factor receptor 3; VEGFR-3; Fms-like tyrosine kinase 4; FLT-4; Tyrosine-protein kinase receptor FLT4

Documentation

User Guide for Antibodies (1077 KB)